Christopher Bowden's most recent trade in Bicara Therapeutics Inc. was a trade of 23,746 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bicara Therapeutics Inc | Christopher Bowden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 23,746 | 23,746 | - | - | Stock Option (Right to Buy) | |
| Alaunos Therapeutics Inc | Christopher Bowden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Alaunos Therapeutics Inc | Christopher Bowden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 40,000 | 44,167 (0%) | 0% | 0 | Common Stock | |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.11 per share. | 18 Jun 2021 | 48,493 | 15,487 (0%) | 0% | 60.1 | 2,914,851 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 50.40 per share. | 18 Jun 2021 | 46,608 | 63,980 (0%) | 0% | 50.4 | 2,349,043 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2021 | 46,608 | 992 | - | - | Stock option (right to buy) | |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2021 | 1,885 | 0 | - | - | Stock option (right to buy) | |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 18 Jun 2021 | 1,885 | 17,372 (0%) | 0% | 39.8 | 74,948 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 17 Jun 2021 | 2,502 | 17,989 (0%) | 0% | 39.8 | 99,480 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 2,502 | 1,885 | - | - | Stock option (right to buy) | |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.02 per share. | 17 Jun 2021 | 2,502 | 15,487 (0%) | 0% | 60.0 | 150,170 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2021 | 20,853 | 4,387 | - | - | Stock option (right to buy) | |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.06 per share. | 09 Jun 2021 | 20,853 | 15,487 (0%) | 0% | 60.1 | 1,252,437 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 09 Jun 2021 | 20,853 | 36,340 (0%) | 0% | 39.8 | 829,115 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 09 Jun 2021 | 7,149 | 22,636 (0%) | 0% | 39.8 | 284,244 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2021 | 7,149 | 25,240 | - | - | Stock option (right to buy) | |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.16 per share. | 09 Jun 2021 | 7,149 | 15,487 (0%) | 0% | 60.2 | 430,117 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 6,675 | 32,389 | - | - | Stock option (right to buy) | |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.07 per share. | 07 Jun 2021 | 6,675 | 15,487 (0%) | 0% | 60.1 | 400,939 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 07 Jun 2021 | 6,675 | 22,162 (0%) | 0% | 39.8 | 265,398 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.04 per share. | 07 Jun 2021 | 4,268 | 15,487 (0%) | 0% | 60.0 | 256,232 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 4,268 | 39,064 | - | - | Stock option (right to buy) | |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 07 Jun 2021 | 4,268 | 19,755 (0%) | 0% | 39.8 | 169,696 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 55.11 per share. | 19 Apr 2021 | 14,401 | 15,487 (0%) | 0% | 55.1 | 793,582 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2021 | 12,513 | 0 | - | - | Stock option (right to buy) | |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.16 per share. | 19 Apr 2021 | 12,513 | 28,000 (0%) | 0% | 35.2 | 439,957 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2021 | 3,210 | 12,513 | - | - | Stock option (right to buy) | |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 55.16 per share. | 19 Apr 2021 | 3,210 | 15,487 (0%) | 0% | 55.2 | 177,055 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.16 per share. | 19 Apr 2021 | 3,210 | 18,697 (0%) | 0% | 35.2 | 112,864 | Common stock |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2021 | 1,888 | 43,332 | - | - | Stock option (right to buy) | |
| Agios Pharma Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 19 Apr 2021 | 1,888 | 29,888 (0%) | 0% | 39.8 | 75,067 | Common stock |